- CDoT teams are collaborating with the Broad's Cancer Program and Bayer Healthcare to target vulnerabilities being uncovered by the systematic genomic and functional characterization of the cancer genome.
- With the Broad Cardiovascular Disease Initiative and Bayer HealthCare, CDoT is leveraging insights from human genetics to help create new cardiovascular therapies.
- Broad and CDoT are partnering with Calico Life Sciences, focused on the biology of aging and therapeutic approaches to diseases of aging.
- Broad and CDoT are collaborating with Deerfield Management on solving complex, early stage therapeutic challenges related to serious unmet medical needs.
- CDoT is partnering with the Stanley Center for Psychiatric Research in translating their insights into the CaV3.3 calcium channel functions, implicated in schizophrenia and the NaV1.2 sodium channel functions, implicated in multiple central nervous system disorders, including intellectual disability, autism and epilepsy into therapeutic projects.
- Through the Slim Initiative in Genomic Medicine for the Americas (SIGMA), CDoT is a key component in a full-scale chemical biology program aimed at developing novel drug leads for treating medullary cystic kidney disease 1(MCKD1), a rare hereditary renal disease.
Current Collaborations and Areas of Focus
Related
News at the broad
News / 03.27.20
News / 03.30.20
